Global Immuno-Oncology Market Briefing And Future Prospects 2022-2028 | Amgen, Inc., Bristol-Myers Squibb Company,


Immuno-oncology

SEATTLE, WASHINGTON, USA, January 7, 2022 /EINPresswire.com/ – Governments in various developing countries have taken initiatives to raise awareness about the different causes of cancer. In order to reduce the death and morbidity rate, governments in developed and developing countries are carrying out awareness campaigns to encourage people to opt for early diagnosis of cancer, which in turn should increase the number of patients at risk of cancer. ” opt for various immunotherapies.

The global immuno-oncology market is estimated to be worth US $ 12,993.8 million in 2020 and is expected to reach US $ 37,783.6 million by the end of 2027.

𝐈𝐦𝐦𝐮𝐧𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲: 𝐃𝐫𝐢𝐯𝐞𝐫𝐬

The R&D of new products is expected to drive the growth of the global immuno-oncology market during the forecast period. For example, in July 2020, Spring Bank Pharmaceuticals, Inc., in partnership with F-star Therapeutics, Limited, launched F-star Therapeutics, Inc. for R&D in immuno-oncology.

Moreover, the R&D in cell therapy is also expected to drive the growth of the global immuno-oncology market during the forecast period. For example, in March 2020, Lonza collaborated with Stanford University School of Medicine, Fred Hutchinson Cancer Research Center, and Parker Institute for Cancer Immunotherapy for cell therapy R&D.

𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://www.coherentmarketinsights.com/insight/request-sample/1271

𝐈𝐦𝐦𝐮𝐧𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲: 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬

R&D in immuno-oncology is expected to offer lucrative growth opportunities for players in the global immuno-oncology market. For example, in January 2020, researchers at the Universidade do Porto, Portugal reported an assessment of the role of O-glycosylation using glyco-engineered gastric cancer models in the detection of CD44v9 – a major splice variant isoform of protein expressed in human gastrointestinal cancer cells – by monoclonal antibody.

In addition, the approval and launch of biosimilars is also expected to provide lucrative growth opportunities for players in the global immuno-oncology market. For example, trastuzumab –– a monoclonal antibody and biosimilar drug has been prequalified by the World Health Organization for the treatment of early breast cancer.

𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬

The major players operating in the global immuno-oncology market are focusing on R&D to expand their product portfolio. For example, Ferring Pharmaceuticals invested around US $ 30 million in February 2018 in the company’s biotechnology center in Switzerland for R&D on monoclonal antibodies and biologics.

𝐈𝐦𝐦𝐮𝐧𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲: 𝐑𝐞𝐬𝐭𝐫𝐚𝐢𝐧𝐭𝐬

Cost is a major issue for much of the population due to limited insurance coverage and government support for cancer treatment. This lack of social health insurance as well as the exclusive provision of private health insurance schemes is a major factor limiting the use of services.

-𝟏𝟗 𝐈𝐦𝐩𝐚𝐜𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

Globally, as of 4:14 p.m. CET on December 29, 2021, 281,808,270 confirmed cases of COVID-19, including 5,411,759 deaths, have been reported to the WHO. As of December 28, 2021, a total of 8,687,201,202 doses of vaccine had been administered. The pandemic has brought changes in patient care, including reduced personal contact but an increase in phone visits and delays in diagnostic procedures.

𝐆𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐇𝐞𝐫𝐞 @ https://www.coherentmarketinsights.com/insight/request-pdf/1271

𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬:

Immune checkpoint inhibitors held a dominant position in the global immuno-oncology market in 2019, accounting for 89.7% share in terms of value, followed by immune system modulators and cancer vaccines respectively.

Immune checkpoint inhibitors held a dominant position in the global immuno-oncology market in 2019, accounting for 89.7% share in terms of value, followed by immune system modulators and cancer vaccines respectively.

𝐈𝐦𝐦𝐮𝐧𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

The major players operating in the global immuno-oncology market are Amgen, Inc., Agilent Technologies Inc., Agenus Inc., AstraZeneca Plc, Avantor, Inc., Bristol-Myers Squibb Company, Bio-Rad Laboratories, Inc. , Dendreon Corporation (A Sanpower Group Company), Enzo Biochem, Inc., Ferring Pharmaceuticals, F. Hoffmann-La Roche Ltd., Lonza Group, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi and Spring Bank Pharmaceuticals, Inc.

𝐈𝐦𝐦𝐮𝐧𝐨-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐊𝐞𝐲 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬

The major players operating in the global immuno-oncology market are focused on the approval and launch of new products to expand their product portfolio. For example, the United States Food and Drug Administration approved Dako PD-L1 IHC 22C3 pharmDx from Agilent Technologies Inc. in June 2018, used to determine PD-L1 expression in cervical cancer. uterus.

𝐍𝐨𝐰 𝐓𝐨 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐥𝐚𝐭 𝟑𝟎% 𝐎𝐅𝐅

𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐀𝐜𝐜𝐞𝐬𝐬 @ https://www.coherentmarketinsights.com/insight/buy-now/1271

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, custom research reports, and advisory services. We are known for our actionable insights and authentic reports in a variety of fields including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually every field. and a comprehensive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reporting. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and continuing to deliver measurable and sustainable results for our clients.

Mr. Shah
Coherent Market Insights Pvt. Ltd.
+1 206-701-6702
write us here
Visit us on social networks:
Facebook
Twitter
LinkedIn
Other



Comments are closed.